Answers are grounded in this paper and cite their sources.
Survival rates of metastatic lung cancer including non-small cell lung cancer (NSCLC) and poor lung cell cancer (SCLC) are poor with a survival rate of less than 5%. The use of cell-oriented therapies has improved the overall survival of the median (OS) in a limited group of NSCLC patients whose tumors undergo certain genetic mutations. However in a large group of NSCLC and SCLC cell mutations are not available to lead to targeted targeted treatment.
No takes yet. Share an insight, caveat, or question.
Dahal Tshetiz (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: